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a b s t r a c t
Introduction: Combined heart surgery and lung resection remain a controversial issue. This
method facilitates the treatment of two major problems with one intervention, reducing
hospitalization cost with acceptable outcomes. On the other hand, skepticism exists related
to the effects of cardiopulmonary bypass on malignancy, proper extent of lung resection
from non-standard approach and to a possible greater risk of perioperative bleeding.
Methods: Between November 2010 and April 2014 ten patients (male 9, female 1) underwent
simultaneous cardiac surgery and pulmonary resection (mean age 69  7 years). Pathologi-
cal ﬁndings were as follows: primary carcinoma 4, benign lesion 4, metastasis 1, and
carcinoid 1. Surgery at right lung was done in ﬁve cases and on left lung in ﬁve cases
(lobectomy 5, extraanatomical resection 1, enucleation 3). In one case, because of the extent
of malignant process, exploration only was done via sternotomy and pneumonectomy was
performed later through thoracotomy. Cardiac procedures were as follows: coronary artery
bypass grafting 5, aortic valve replacement 3, mitral valve replacement 1, ascending aorta
replacement 1, and MAZE procedure 3. Sternotomy was performed in eight patients; in two
of them left lateral thoracotomy was used and coronary artery revascularization was
performed with MIDCAB principle. Off-pump surgery was used four times.
Results: There was no hospital mortality. There was no reexploration because of bleeding.
Cardiac part of procedures was in all cases without complications. Prolonged air-leak was
found in one case. All patients with benign pathology are alive. In the malignant group, one
patient with staged approach died in terminal phase of disease and the second patient
deceased because of disease-non-related reasons one year after surgery. The rest of them
are followed up regularly by pneumo-oncology outpatient department.
Conclusion: Combined heart surgery and lung resection can be performed without increased
mortality and/or morbidity. The synchronous treatment avoids the necessity of a second
intervention with good results and economic beneﬁts.
# 2015 The Czech Society of Cardiology. Published by Elsevier Sp. z o.o. All rights
reserved.
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Combined heart surgery and lung resection remain a contro-
versial issue. This method facilitates the treatment of two
major problems in one intervention with acceptable outcomes
and overall cost reduction. With increasing age and frailty of
the patient population, it is sometimes very difﬁcult to
perform two major surgeries during short time interval. Even,
because of primary heart surgery complications, planned lung
tumor resection can be delayed into the already inoperable
condition due to malignancy spread. Psychological factor can
also play an important factor, and few patients wish to have
second extensive surgery.
The combined heart revascularization with lung resection
was ﬁrst reported by Dalton [1] in 1977 and Girardet [2] in 1981.
In 1985, Piehler [3], on his 41 patients, concluded that it is
possible to perform both procedures from sternotomy safely at
the same time. On the other hand, skepticism exists related to
the effects of cardiopulmonary bypass on malignancy and to a
possible greater risk for perioperative bleeding. There are also
concerns about completeness of pulmonary resection and
staging from non-standard sternotomy approach. The purpose
of this report is to present our experience with the combined
surgical approach and evaluate its beneﬁts and safety.
Patients and methods
We present a series of ten patients who underwent combined
surgical treatment for heart and lung disease in a one-step
procedure between November 2010 and April 2014. There
were nine males and one female. Their mean age was 69
(range: 59–79) years. Five patients were presented with a
documented lung tumor and a concomitant heart disease.
These were as follows: aortic stenosis; combined aorto-mitral
disease with paroxysmal atrial ﬁbrillation; aortic stenosis
with dilatation of ascending aorta; ischemic heart disease and
acute non-transmural myocardial infarction. In the otherTable 1 – List of patients, lung tumor localization, heart surger
No. Sex Age Tumor
localization
Lun
1 M 59 LUL Enuc
2 M 71 LLL Explo
3 M 66 RUL Lobe 
4 M 67 RML Lobe 
5 M 68 LUL Lobe 
6 F 74 LUL Wedg
7 M 79 RML Enuc
8 M 65 RLL Enuc
9 M 76 LLL Lobe 
10 M 65 LLL Lobe 
LUL, left upper lobe; LLL, left lower lobe; RUL, right upper lobe; RML, righ
MVR, mitral valve replacement; CABG, coronary artery bypass grafting; M
anterior descending artery.group in ﬁve of the patients, pulmonary tumor was acciden-
tally discovered on preoperative chest X-ray when cardiac
procedure was planned.
The standard preoperative assessment included chest X-
rays, computer tomography, lung function testing, echocardi-
ography and coronary angiography. All patients were operated
on the basis of an absence of mediastinal lymphadenopathy
and metastatic disease according to the results of their
preoperative evaluation.
After induction of general anesthesia, all the patients had a
double lumen endotracheal tube positioned in order to achieve
one-lung ventilation. Standard middle sternotomy was used in
eight patients. Access to the chest cavity was gained through
widely opened pleura on the affected side. Pulmonary surgery
was carried out and a frozen pathological analysis was
performed immediately. According to histopathology result
the extent of resection was carried out. Left upper lobe was
affected in three cases and left lower lobe in three cases. Right
upper lobe was affected in one case, right middle lobe in two
cases and right lower lobe in one case. Pulmonary lobectomy
was performed in ﬁve cases, extraanatomical resection in one
case and simple lesion enucleation in three cases respectively.
In one case of previously known malignant tumor, more
progressed disease with left hilus affection enforced us to
indicate staged procedure – left lung resection with
lymphadenectomy was carried out a month later from left
thoracotomy. After lung resection, hemostasis was secured
and heparinization instituted. Opened cardiac procedures
were performed on CPB (cardio-pulmonary bypass) with
antegrade cold blood cardioplegia. Off-pump approach for
revascularization was used in two sternotomy cases. Prior to
chest closure, chest drain was inserted into the pleural cavity.
Mediastinum was drained with redon drains as ordered by
department long-term experience.
In two patients with known left lung tumor and localized
left anterior descending artery (LAD) stenosis (one with
NSTEMI), left thoracotomy approach was used because of
our experience with MIDCAB surgery. In these cases LIMA
harvesting and heart revascularization were performed ﬁrsty and tumor histopathology.
g surgery Heart surgery Tumor
leation AVR, MAZE Hamartoma
ration AVR Primary CA
resection AVR, MVR, MAZE Primary CA
resection CABG 2 Metastasis
resection CABG 4 Carcinoid
e resection CABG 3 Lung infarction




leation CABG 2 Hamartoma
resection MIDCAB (LAD) Primary CA
resection MIDCAB (LAD) Primary CA
t middle lobe; RLL, right lower lobe; AVR, aortic valve replacement;
IDCAB, minimally invasive direct coronary artery bypass; LAD, left
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tration. All patients were transferred to the ICU in the
immediate postoperative period and extubated after hemody-
namic and ventilatory parameters stabilization.
Results
None of the patients required re-exploration for excessive
bleeding. There was no hospital mortality. Cardiac part of the
procedures was in all cases without major complications.
Prolonged air-leak was found in one case. All surgical wounds
were healed per primam. According to histopathology, four
benign lesions were diagnosed (hamartoma 2, lung infarction
2). Six malignant tumors were conﬁrmed (adenocarcinoma 3,
spinocellular carcinoma 1, carcinoid 1, metastasis 1). All
patients with benign pathology are alive. In the malignant
group, the patient with staged approach died in terminal
phase of disease (with prosthetic valve endocarditis as a
complication) and the second patient died because of acute
pancreatitis (one year after surgery). The others are followed
up by pneumo-oncology outpatient department. Patients, lung
tumor localization, type and surgical procedures are listed in
Table 1.
Discussion
Concomitant surgical diseases of the heart and lungs are
uncommon. The majority of these patients present with
cardiac disease and are found incidentally to have an
asymptomatic indeterminate pulmonary mass. Less frequent-
ly, patients present with pulmonary disease and are found to
have signiﬁcant cardiac disease that would increase the risk of
pulmonary resection [4]. Options for therapy include either
simultaneous or staged procedures for these disease process-
es. Some surgeons are reluctant to perform pulmonary
resection for lung cancer at the time of a cardiac procedure
that requires extracorporeal circulation because of potential
increased bleeding from heparinization and extracorporeal
circulation, compromised exposure for pulmonary resection
via median sternotomy and possible alterations of the
immune system leading to proliferation of lung cancer. In
contrast, concomitant correction of both disease entities
avoids the need for a second procedure and is advantageous
if morbidity and mortality are not increased.
Median sternotomy is the preferred approach for com-
bined heart and lung surgery. It is associated with less pain,
reduced analgesic requirements, faster recovery of pulmo-
nary function, and fewer pulmonary complications [5]. Lung
resection through median sternotomy seems to be better
tolerated even in patients with impaired pulmonary function
and decreased pulmonary reserve [6]. Nevertheless, left lower
lobectomy is believed technically to be the most difﬁcult to
perform with median sternotomy. In our group of patients,
sternotomy approach was used in eight patients. Two left
lower lobectomies were performed from left thoracotomy and
heart revascularization was performed according to MIDCAB
technique. In one patient with left lower lobe and hilus
involvement, because of compromised exposure and localextent of the disease, the treatment was staged. Left lung
resection was performed from thoracotomy approx. one
month later.
Patients who undergo heart surgery with CPB are at
substantial risk of postoperative bleeding [7]. Bleeding can
result from excessive heparinization, inadequate heparin
neutralization or protamine excess. More commonly it is the
result of a transient impairment of platelet function mediated
by platelet activation during passage through the extra-
corporeal circuit. In patients undergoing a concomitant
procedure, bleeding may arise both from the area of the lung
resection and mediastinal node dissection and accounts for a
signiﬁcant cause of postoperative morbidity [8]. In our group of
patients, we did not observe greater than average blood loss
and no re-exploration for bleeding was necessary.
Revascularization without CPB (off-pump) can signiﬁcantly
reduce postoperative bleeding and transfusion requirements.
Pulmonary dysfunction sustained during CPB (ﬂuid overload,
activation of the inﬂammatory response) can also be pre-
vented by off-pump approach. To reduce these risks in our
group, patients with suitable coronary artery anatomy under-
went revascularization without CPB. When CPB usage was
necessary, lung resection was performed ﬁrst prior to heparin
institution.
There has been concern expressed regarding alterations in
the immune system following cardiopulmonary bypass which
can enhance malignant growth and decrease long term
survival in patients with coexisting cancer. However, the
speciﬁc effects of CPB on tumor growth and dissemination in
patients with coexistent malignant disease remain largely
unknown. A transient perioperative depression of immune
function may provide window for malignant growth and
dissemination in patients with coexisting disease. By perform-
ing simultaneous procedures and resecting the tumor prior to
commencement of CPB or avoiding the use of CPB completely,
these effects are minimized which may improve the long-term
survival. Several authors demonstrated that in patients
undergoing combined surgery, long-term survival is improved
if the lung cancer is resected prior to CPB compared with
during or after CPB [9,10]. However, there does not appear to be
an increase in cancer recurrence in patients with previously
treated malignant conditions who subsequently undergo
cardiac surgery [11,12].
Long-term survival after combined treatment is mostly
related to the predicted survival after lung resection. This
depends on T stage and mostly on the patient's nodal status.
These parameters must be thoroughly evaluated preopera-
tively. Hilar and mediastinal lymph node sampling and
dissection can be carried out through median sternotomy,
although it is considered more difﬁcult [13]. Inadequate lymph
node evaluation and incomplete dissection are by some
authors considered to be an important factor of poor long-
term outcome in patients undergoing combined treatment
[14]. Although radical mediastinal lymphadenectomy theoret-
ically allows more accurate nodal staging, there are no data
clearly promising survival beneﬁts.
Still, majority of studies subscribing combined treatment
include a small number of patients and there are no controlled
randomized trials comparing the combined surgical treatment
with two-stage procedure [15,16].
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According to our very limited series of patients, combined
treatment of cardiac disease and lung cancer is a feasible and
safe method with good results. It can be carried out with
accepted mortality and morbidity. It gives a good chance for
deﬁnitive cure for patient and economic beneﬁts. When
indeterminate pulmonary mass at the time of cardiac operation
is present, concomitant wedge excision should be performed if
possible. If benign, the lesion will be appropriately managed and
a second procedure will be avoided. If the lesion is malignant,
the decision to proceed with a combined pulmonary resection
should be individualized. In the attempt to minimize blood loss
and theoretical CPB-induced tumor dissemination, off-pump
revascularization techniques are preferred. In selected cases
with suitable coronary anatomy, combined procedure can be
performed from lateral thoracotomy using MIDCAB principles,
especially in patients with left lower lobe affection. In cases with
open heart surgery and CPB installation, lung resection should
be performed ﬁrst. More advanced neoplasms that may require
pneumonectomy, chest wall reconstruction, difﬁcult nodal
examination and those that have extensive pleural adhesions,
should be resected at a later staged procedure.
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